手术前后联合化疗对非小细胞肺癌患者生存质量及不良反应的影响

摘要

Objective:To explore the effects of combined chemotherapy before and after operation on survival quality and adverse reactions in patients with non-small cell lung cancer (NSCLC).Methods:Ninety-six patients with NSCLC from January 2010 to 2015 were divided into control group and research group according to the order of admission,48 patients in each group.The control group was treated with surgery combined with postoperative chemotherapy,the research group was treated with neoadjuvant chemotherapy on the basis of control group.After treatment,short-term efficacy,changes of tumor marker levels before and after surgery,survival rate and adverse reactions of the two groups were compared.Results:The ORR and survival rate in the research group were significantly higher than that of the control group(P＜ 0.05).After surgery,the level of tumor markers was significantly lower than that of the control group(P ＜0.01),there was significant difference in two groups.There were no significant difference in the adverse reactions between the two groups (P＞ 0.05).Conclusion:Combined chemotherapy before and after surgery in the treatment of NSCLC can effectively improve efficacy,quality of life and don't increase adverse reactions,which has important application value.%目的:探讨手术前后联合化疗对非小细胞肺癌(NSCLC)患者生存质量及不良反应的影响.方法:选取2010-01～2015-01我院诊治的NSCLC患者96例为研究对象,根据入院顺序分为对照组和研究组,每组48例.对照组采用手术联合术后化疗治疗,研究组在对照组的基础上采用术前新辅助化疗.比较治疗结束后两组患者的近期疗效、手术前后各肿瘤标志物水平变化、生存率及不良反应发生率.结果:研究组患者ORR及生存率显著高于对照组(P＜0.05),术后各肿瘤标志物水平降低程度显著优于对照组,差异有统计学意义(P＜0.01);两组不良反应发生率比较无显著性差异(P＞0.05).结论:手术前后联合化疗可有效提高NSCLC患者的近期疗效及生存质量,且不增加不良反应,具有重要的临床应用价值.